Global Orthopedic Regenerative Surgical Products Market Grows Steadily at a CAGR of 3.56%

Regenerative orthopedics employs contemporary technology to encourage and speed healing. The enhancement of implants and the creation of novel minimally invasive arthroscopic technical abilities improved initial, mid-term, and long-term patient outcomes and short-term patient morbidity. In order to hasten the healing process, biological and regenerative adjuncts have emerged in the pursuit of continuous improvement. Various primary and supplementary regenerative therapies, including preparations made from bone marrow, growth factors, and stem cells, are becoming more widely accessible. Market Dynamics Rising Prevalence of Orthopedic Conditions Drives the Global Market Osteoarthritis is a leading cause of physical discomfort and incapacity, particularly among the aged population. In the United States, knee, hip, and other joint replacement surgeries are the most often performed elective procedures. As a result of alterations in lifestyle and improved access to healthcare, a rise in the proportion of younger patients is anticipated. According to NerdWallet Health, the typical American adult over 25 will undergo knee replacement surgery at some point during his lifetime. Consequently, increasing surgical procedures will drive product demand over the forecast period. Rising R&D Exercises and Technological Progress Creates Tremendous Opportunities New technologies like stem cells, viscosupplements, Platelet Rich Plasma (PRP) therapies, and technological developments supported by rising R&D studies are projected to drive the orthopedic regenerative surgical goods market. PRP and stem cell-based therapies are at the forefront of research in regenerative medicine for indications like osteoarthritis, trauma healing, and repair of damaged tissues. According to a retrospective study published in November 2020 by Amniox Medical, amniotic membrane/umbilical cord particles were found to considerably postpone total knee arthroplasty (TKA) in patients with moderate to severe knee osteoarthritis. The market is growing due to more people using synthetic bone grafts containing HAP/TCP since they are more biocompatible than other types. Regional Analysis  North America is the most significant shareholder in the global orthopedic regenerative surgical products market and is expected to grow at a CAGR of 3.50% during the forecast period. The superior healthcare infrastructure in the region encourages market expansion. Favorable reimbursement regulations and a high priority on the quality of healthcare services in the area stimulate market demand. The regional market is competitive because there are significant market players. Players with a solid local presence, such as Baxter, Zimmer Biomet, and Stryker, have helped the local market grow. Europe is expected to grow at a CAGR of 3.80%, generating USD 1,677.24 million during the forecast period. When the COVID-19 epidemic first broke out, several governments in the area stopped all non-emergency surgical procedures to free up resources, particularly healthcare professionals, to care for patients with coronavirus infection—this limited market growth in 2020. But in the following years, the region's resurgence in surgery will help increase demand for surgical supplies. The fundamental forces driving market expansion are an aging population more prone to ailments and rising consumer awareness of potential treatments. Key Highlights The global orthopedic regenerative surgical products market was valued at USD 4.02 billion in 2021. It is projected to reach USD 5.70 billion by 2030, growing at a CAGR of 3.95% during the forecast period (2022-2030). Based on product, the global orthopedic regenerative surgical products market is bifurcated into allograft, synthetic, cell-based, and viscosupplements. The allograft segment is the highest contributor to the market and is expected to grow at a CAGR of 4.10% during the forecast period. Based on application, the global orthopedic regenerative surgical products market is bifurcated into orthopedic pain management, trauma repair, cartilage and tendon repair, joint reconstruction, and others. The joint reconstruction segment owns the highest market share and is expected to grow at a CAGR of 4.15% during the forecast period. Based on end-user, the global orthopedic regenerative surgical products market is bifurcated into hospitals, ambulatory surgical centers, and others. The hospital segment is the highest contributor to the market and is expected to grow at a CAGR of 4.00% during the forecast period. North America is the most significant shareholder in the global orthopedic regenerative surgical products market and is expected to grow at a CAGR of 3.50% during the forecast period. Competitive Players The global orthopedic regenerative surgical products market's major key players are Anika Therapeutics, Inc., Vericel Corporation, Baxter, Zimmer Biomet, Stryker, Smith & Nephew, AlloSource, Amniox Medical, Inc., VSY Biotechnology, Aptissen S.A., MiMedx, and Arthrex, Inc. Market News In March 2022, Zimmer Biomet Holdings, Inc, a global medical technology leader, announced the release of WalkAI™, a dynamic artificial intelligence (AI) model that identifies patients who are predicted to have a lower gait speed outcome at 90 days after hip or knee surgery. Global Orthopedic Regenerative Surgical Products Market: Segmentation By Product Allograft Synthetic Cell-based Viscosupplements By Applications Orthopedic Pain Management Trauma Repair Cartilage and Tendon Repair Joint reconstruction Others By End-User Hospitals Ambulatory Surgical Center Others By Regions North America Europe Asia-Pacific LAMEA